RxDoctor Payments Data

Shariq Afridi, MD

Gastroenterology · Hamilton Sq, NJNPI 1467436170

Payments from drug & device makers

$1,676in general payments, 2019–2025

Across 94 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$564
  • Pfizer$309
  • Nestle Healthcare Nutrition Inc.$142
  • Amgen$99
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$98
  • Johnson & Johnson$91
  • plus $373 from 9 others

What the payments were for

  • Consulting fees$352%
  • Food & beverage$1,60496%
  • Education$372%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,676 in reported general payments places this provider in the 40th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$140,144
Medicare patients
512
Services billed
1,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$286,929
CreonLipase/Protease/Amylase33$127,721
EntyvioVedolizumab14$120,199
LinzessLinaclotide75$60,870
Dexlansoprazole DrDexlansoprazole60$19,663
Mesalamine27$12,530
Pantoprazole Sodium858$12,456
Lansoprazole14$5,166
Lubiprostone30$3,529
Esomeprazole Magnesium91$2,507
Omeprazole50$1,078
Famotidine49$659
Azelastine Hcl26$597
Dicyclomine Hcl16$150
Fluconazole16$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$91$286,92911 claims
AbbVieCreon, Linzess$29$188,592108 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$564$120,19914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Hamilton Sq

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →